Emergent BioSolutions to Participate in Investor Conferences
August 23, 2021 16:05 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following...
Emergent BioSolutions Reports Financial Results For Second Quarter 2021
July 29, 2021 16:05 ET
|
Emergent BioSolutions
Reaffirms 2021 Full Year Forecast for Revenues and Profit GAITHERSBURG, Md., July 29, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second...
Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility
July 29, 2021 07:25 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., July 29, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) is allowing Emergent’s Bayview...
Reverse the Silence Campaign Casts a National Spotlight on Overdose Risks Associated with Opioid Use
July 26, 2021 09:01 ET
|
Emergent BioSolutions
Emergent BioSolutions joins forces with an alliance of advocacy organizations that share a common goal to empower open communication and address the stigma of opioid overdoses, which are oftentimes...
Emergent BioSolutions to Release Second Quarter 2021 Financial Results and Conduct a Conference Call on July 29, 2021
July 15, 2021 06:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., July 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, July 29, 2021 at 5:00 pm eastern time to discuss the financial...
COVID-19 Vaccine Drug Substance Manufactured by Emergent BioSolutions Authorized as Part of Johnson & Johnson’s Emergency Use Authorization
June 11, 2021 16:35 ET
|
Emergent BioSolutions
Emergent continues to work with the FDA to address identified observations at Bayview facility in order to release additional batches and resume production GAITHERSBURG, Md., June 11, 2021 (GLOBE...
Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus Virus-Like Particle Vaccine Candidate
May 26, 2021 06:30 ET
|
Emergent BioSolutions
A dose-related increase in immune response, as measured by anti-chikungunya virus serum neutralizing antibodies (SNA), was previously observed. Two years post-vaccination, SNA mean titers were 19...
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 20, 2021 at 9:00am EDT
May 06, 2021 06:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., May 06, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2021 Annual Meeting of Stockholders will be held in a virtual-only format via live...
Emergent BioSolutions to Participate in Investor Conferences
May 05, 2021 16:05 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following...
Emergent BioSolutions Reports Financial Results for First Quarter 2021
April 29, 2021 16:05 ET
|
Emergent BioSolutions
Revises 2021 Financial Forecast GAITHERSBURG, Md., April 29, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the quarter ended March 31, 2021. ...